Intrinsiqs

Is Cytokinetics, Incorporated overvalued?

Cytokinetics, Incorporated (CYTK) — key valuation metrics and fundamentals.

No verdict
Price
$64.66
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$8.05B
Dividend yield
0.0%
Return on equity
164.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CYTK's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.